Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes

Figure 4

Fluid removal from the abdomen was poor in mice with liver cirrhosis, but was improved by dapagliflozin. (a) Representative views of the abdominal fluid over time (from left to right), obtained using microCT. Coronal (top), sagittal (middle), and axial (bottom) views. (b) Abdominal fluid volumes in mice fed each diet for 17 weeks ( per group). and vs. the HFD- or NCD-fed groups. (c) Effects of each treatment on abdominal fluid removal in HFD + MCDD-fed mice. for each treatment group. and vs. dapagliflozin- (top) or furosemide- (bottom) treated mice. ^†vs. 1.0 mg/kg/day dapagliflozin-treated mice. ^¶vs. 30 mg/kg/day furosemide-treated mice.

(a)

(b)

(c)